Collecting and studying samples from people with urothelial carcinoma and related urinary tract cancers
Collects and studies body samples and health data from adults with urothelial carcinoma.
Plain-language title generated from the registry record
Registry title: Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
Key facts
- Where
- Houston, United StatesSee the site
Where in United States
- UT MD Anderson Cancer CenterHouston, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- M.D. Anderson Cancer Center
- Trial code
- NCT07789119
- Record updated
- 5 October 2026
- Original description
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.Read full original descriptionShow less
Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
Exclusion: No known or suspected urothelial carcinoma or other related malignancy of the urinary tract, and no clinical circumstance in which enrollment under this protocol is relevant to the study objectives; Age younger than 18 years; Unable to understand the study information or unable to personally provide informed consent; Declines participation; Clinical, operational, or safety circumstances that make enrollment or research collection inappropriate or not feasible in the judgment of the treating clinical team or study investigators. Examples may include urgent clinical priorities, insufficient residual specimen after diagnostic needs are met, inability to safely obtain research specimens during a clinically indicated procedure, or inability to complete consent appropriately; Prisoners or other populations requiring additional regulatory protections not specifically approved under this protocol.
Eligibility Criteria; Participants must meet all of the following criteria for enrollment:; Age 18 years or older at the time of consent; Known or suspected urothelial carcinoma or other related malignancy of the urinary tract for which biospecimen and associated clinical data collection is relevant to the objectives of this protocol. This may include patients undergoing diagnostic evaluation for a lesion, mass, abnormal cytology, or other clinical finding concerning for malignancy; Undergoing evaluation, treatment, surveillance, follow-up care, or clinically indicated procedures at The University of Texas M.D. Anderson Cancer Center, including Houston Area Locations; Able to understand and personally provide informed consent; Willing to allow prospective collection, banking, storage, and research use of biospecimens and associated clinical information as described in the informed consent document.